A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: * To compare 12 weeks\' efficacy of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. . * To compare the tolerability of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. .
Epistemonikos ID: 5c1f6f314e2965d05a8050ab30042667c20d451b
First added on: May 10, 2024